Expanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis Demand

Catalysts

About Cannara Biotech

Cannara Biotech is a vertically integrated Canadian cannabis producer focused on premium branded products at competitive price points.

What are the underlying business or industry changes driving this perspective?

• Expanding cultivation and processing capacity at Valleyfield and activating 3 additional grow rooms, each with the potential to generate over $10 million in annual net revenue, positions the company to support higher volumes while spreading fixed costs over more output. This can influence both revenue and net margins.
• Growing national retail market share to 4.4% in a flat Canadian retail market, together with strong brand positions in Quebec and momentum in provinces such as Ontario and British Columbia, ties the business to the gradual shift from illicit to legal cannabis consumption. This can affect top-line revenue and operating leverage.
• Deeper product penetration through new genetics and larger format offerings, including upcoming 14 gram packs under Tribal and an expanded Flavor Bomb line across infused pre-rolls and vapes, aligns with consumer preference for branded, higher potency formats. This can support revenue per gram and gross margins.
• Development of an EU GMP post-harvest facility and active relationship-building in European markets creates optionality to redirect excess Canadian inventory from low-priced B2B channels to export opportunities. This may impact revenue mix and earnings quality if a higher price per gram is achieved.
• Consistent positive adjusted EBITDA over 20 consecutive quarters, growing operating cash flow and a reinforced balance sheet, including the $6.3 million investment at a premium share price and access to lower-cost credit, give the company room to continue investing in capacity, R&D and commercial capabilities in a sector where weaker peers may retrench. This can influence earnings resilience and cash generation.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Cannara Biotech's revenue will grow by 15.7% annually over the next 3 years.
• Analysts assume that profit margins will increase from 9.0% today to 20.8% in 3 years time.
• Analysts expect earnings to reach CA$36.3 million (and earnings per share of CA$0.26) by about April 2029, up from CA$10.2 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CA$41.4 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 12.9x on those 2029 earnings, down from 17.7x today. This future PE is lower than the current PE for the CA Personal Products industry at 17.7x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.83%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Cannara is adding significant cultivation and processing capacity at Valleyfield and preparing 3 additional grow rooms, yet the Canadian retail cannabis market was essentially flat year over year and declined 4% quarter over quarter. If long term domestic demand remains muted, excess capacity and higher inventory of $48.6 million could weigh on pricing, revenue per gram and ultimately revenue and earnings.
• The company relies heavily on category leadership in Quebec, including approximately 14.3% provincial share and roughly 25% to 26% vape share, while share in provinces such as Ontario is materially lower at around 3.7%. If growth outside Quebec stalls or requires higher marketing and shelf space payments, rising sales and marketing and G&A costs near 10% of sales each could continue to pressure operating income and net margins.
• Management is building an EU GMP post harvest facility to create export optionality and reduce reliance on low priced B2B sales, but if European regulatory timelines, competitive intensity or pricing do not support attractive margins, the additional capital tied up in property, plant and equipment of $89.7 million and export infrastructure may not translate into higher revenue mix or earnings quality.
• Operating income for the quarter was $3.3 million compared to $5.9 million a year earlier and adjusted EBITDA margin moved to 22% from $7.1 million of adjusted EBITDA in the prior year. If ongoing investments in sales, marketing, R&D and middle management do not translate into sustained share gains or pricing power, the long term trend could be structurally lower net margins and slower earnings growth than implied by the current expansion plan.
• The business model leans on premium quality at competitive price points and high margin categories such as infused pre rolls and vapes, yet Canadian retail sales softened seasonally and wholesale revenue declined by $1.4 million year over year. If category mix shifts, regulatory changes on THC caps or further price compression persist across the sector, this could pressure revenue per unit, gross margin of 43% and the ability to keep generating free cash flow while funding capacity growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CA$3.19 for Cannara Biotech based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CA$174.9 million, earnings will come to CA$36.3 million, and it would be trading on a PE ratio of 12.9x, assuming you use a discount rate of 6.8%.
• Given the current share price of CA$1.82, the analyst price target of CA$3.19 is 42.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.